In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene

被引:20
作者
Egorin, MJ
Rosen, DM
Benjamin, SE
Callery, PS
Sentz, DL
Eiseman, JL
机构
[1] UNIV MARYLAND, SCH MED, DEPT MED, DIV HEMATOL ONCOL, BALTIMORE, MD 21201 USA
[2] UNIV MARYLAND, SCH PHARM, DEPT PHARMACEUT SCI, BALTIMORE, MD 21201 USA
[3] UNIV MARYLAND, SCH MED, DEPT PATHOL, BALTIMORE, MD 21201 USA
关键词
halomon; natural products; halogenated monoterpenes; cytochrome P450;
D O I
10.1007/s002800050701
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To characterize the enzymes responsible for and metabolites produced from the metabolism of halomon, a halogenated monoterpene that is isolated from the red algae Portieria hornemanii and has in vitro activity in the NCI screen against brain, renal, and colon cancer cell lines. Materials and methods: Mouse and human liver fractions: prepared by homogenization and differential centrifugation, were incubated with halomon, extracted with toluene, and analyzed by gas chromatography. Results: In the presence of NADPH, mouse-liver 9,000-g supernatant (S9) fractions metabolized halomon, but boiled S9 fractions did not. NADH could not substitute for NADPH. Further separation of murine hepatic S9 fractions produced a microsomal fraction that contained all of the halomon-metabolizing activity; cytosol had none. Carbon monoxide reduced murine hepatic microsomal metabolism of halomon, whereas an anaerobic, N-2 environment greatly accelerated the disappearance of halomon. Human hepatic microsomes metabolized halomon and required NADPH to do so. Carbon monoxide completely inhibited human hepatic microsomal metabolism of halomon. Unlike murine hepatic microsomal metabolism of halomon, anaerobic conditions did not enhance the metabolism of halomon by human hepatic microsomes. Neither 100 mu M diethyldithiocarbamate, 1 mu M quinidine, 100 mu M ciprofloxacin, 3 mu M ketoconazole, nor 100 mu M sulfinpyrazone inhibited the metabolism of halomon by human hepatic microsomes. Both murine and human hepatic microsomes produced a metabolite of halomon. The mass spectrum of this metabolite indicated the loss of one chlorine atom and one bromine atom. Conclusions: Halomon is metabolized by mouse and human hepatic cytochrome P-450 enzymes, the identities of which remain unknown. Hepatic metabolism of halomon is very consistent with the concentrations of halomon measured in mouse tissues and urine after i.v. administration of the drug.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 11 条
[1]  
BOYD MR, 1992, DEV ONCOL, V68, P11
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes [J].
Crewe, HK ;
Ellis, SW ;
Lennard, MS ;
Tucker, GT .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :171-178
[4]   Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii [J].
Egorin, MJ ;
Sentz, DL ;
Rosen, DM ;
Ballesteros, MF ;
Kearns, CM ;
Callery, PS ;
Eiseman, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 39 (1-2) :51-60
[5]   ISOLATION AND STRUCTURE-ACTIVITY FEATURES OF HALOMON-RELATED ANTITUMOR MONOTERPENES FROM THE RED ALGA PORTIERIA-HORNEMANNII [J].
FULLER, RW ;
CARDELLINA, JH ;
JUREK, J ;
SCHEUER, PJ ;
ALVARADOLINDNER, B ;
MCGUIRE, M ;
GRAY, GN ;
STEINER, JR ;
CLARDY, J ;
MENEZ, E ;
SHOEMAKER, RH ;
NEWMAN, DJ ;
SNADER, KM ;
BOYD, MR .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (25) :4407-4411
[6]   A PENTAHALOGENATED MONOTERPENE FROM THE RED ALGA PORTIERIA-HORNEMANNII PRODUCES A NOVEL CYTOTOXICITY PROFILE AGAINST A DIVERSE PANEL OF HUMAN TUMOR-CELL LINES [J].
FULLER, RW ;
CARDELLINA, JH ;
KATO, Y ;
BRINEN, LS ;
CLARDY, J ;
SNADER, KM ;
BOYD, MR .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) :3007-3011
[7]   ROLE OF HUMAN CYTOCHROME-P-450-IIE1 IN THE OXIDATION OF MANY LOW-MOLECULAR-WEIGHT CANCER SUSPECTS [J].
GUENGERICH, FP ;
KIM, DH ;
IWASAKI, M .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (02) :168-179
[8]  
JamisDow CA, 1995, CANCER CHEMOTH PHARM, V36, P107
[9]   OXIDATIVE AND REDUCTIVE METABOLISM BY CYTOCHROME-P450-2E1 [J].
KOOP, DR .
FASEB JOURNAL, 1992, 6 (02) :724-730
[10]   DISPLAY AND ANALYSIS OF PATTERNS OF DIFFERENTIAL ACTIVITY OF DRUGS AGAINST HUMAN-TUMOR CELL-LINES - DEVELOPMENT OF MEAN GRAPH AND COMPARE ALGORITHM [J].
PAULL, KD ;
SHOEMAKER, RH ;
HODES, L ;
MONKS, A ;
SCUDIERO, DA ;
RUBINSTEIN, L ;
PLOWMAN, J ;
BOYD, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (14) :1088-1092